[1] R. N. Pinckard, A NEW CLASS OF LIPID. J Biol Chem. 254 (2020) 9355_9358.
[2] P. Detopoulou and T. Nomikos, Platelet Activating Factor in Heart Failure : Potential Role in Disease Progression and Novel Target for Therapy,Curr. Heart. Fail. Rep. 10 (2013) 122–129.
[3] R. Lordan, A. Tsoupras and I. Zabetakis, The Potential Role of Dietary Platelet-Activating Factor Inhibitors in Cancer Prevention and Treatment, Amer. So. for Nut. 10 (2019) 148–164.
[4] V. Melnikova and M. Bar-eli, Inflammation and melanoma growth and metastasis : The role of platelet-activating factor ( PAF ) and its receptor, Cancer Meta. Rev 26 (2009) 359–371.
[5] V. O. Melnikova and M. Bar-eli, Inflammation and melanoma metastasis, Pigment Cell Melanoma Res. 22 (2007) 257–267.
[6] L. El Mchichi, A. Belhassan, A. Aouidate, A. Ghaleb, T. Lakhlifi and M. Bouachrine, QSAR study of new compounds based on 1,2,4-triazole as potential anticancer agents, Phys. Chem. Res. 8 (2020) 125–137.
[7] J. Summers and D. H. Albert, Platelet Activating Factor Antagonists, Adv. in Pharm. 32(1995).
[8] V. D. Papakonstantinou, N. Lagopati, E.C. Tsilibary, C. A. Demopoulos and A. I. Philippopoulos, A Review on Platelet Activating Factor Inhibitors : Could a New Class of Potent Metal-Based Anti-Inflammatory Drugs Induce Anticancer Properties ?, Bioi. Chem and App 2017 (2017) 1_19.
[9] S. P. Bhatia, D. Mcginty, C. S. Letizia and A. M. Api, Fragrance material review on cedrol, Food and Chem. Tox. 46 (2008)100–102.
[10] H. O. Yang, D. Sal, and B. Ha, Isolation and Characterization of Platelet-Activating Factor Receptor Binding Antagonists from Biota orientalis.Planta Med. 61 (1995).
[11] T. Y. Shen , S. Hwang, N. M. Chang, T. M. Doebber, M. T. Lam, M. S. Wu, X. Wang, G. Q. Han and R. Z. Li, Characterization of a platelet-activating factor receptor antagonist isolated from haifenteng (Piper futokadsura): Specific inhibition of in vitro and in vivo platelet-activating factor-induced effects, Proc. Nati. Acad. Sci. 82 (1985) 672–676.
[12] L. El Mchichi, A. El Aissouq, A. Belhassan, R, El-Mernissi, A. Ouammou, T. Lakhlifi, M. Bouachrine, “Materials Today : Proceedings In silico design of novel Pyrazole derivatives containing thiourea skeleton as anti-cancer agents using : 3D QSAR , Drug-Likeness studies , ADMET prediction and molecular docking,” Mater. Today Proc., 2021, doi: 10.1016/j.matpr.2021.03.152.
[13] A. Adamski, D. Kruszka, Z. Dutkiewicz, M. Kubicki, V. Patroniak and A. Gorczy, Novel family of fused tricyclic [1, 4] diazepines : Design , synthesis , crystal structures and molecular docking studies,Tetrahedron 73 (2017) 3377–3386.
[14] S. K. Ling, M. M. Pisar and S. Man, Platelet-Activating Factor ( PAF ) Receptor Binding Antagonist Activity of the Methanol Extracts and Isolated Flavonoids from Chromolaena odorata ( L .) KING and ROBINSON, Biol. Pharm. Bull. 30 (2007) 1150–1152.
[15] M. Clark, R. D. Cramer and N. Van Opdenbosch, Validation of the General Purpose Tripos5 . 2 Force Field,J. of Comp. Chem. 8 (1989) 982–1012.
[16] W. P. Purcell and J. A. Singer, A Brief Review and Table of Semiempirical Parameters Used in the Huckel Molecular Orbital Method, J. of Chem. and Eng. Data 12 (1967) 235_246.
[17] O. Trott and A. J. Olson, Software News and Update AutoDock Vina : Improving the Speed and Accuracy of Docking with a New Scoring Function , Efficient Optimization , and Multithreading,J. of Comp. Chem. 2 (2009) 456_461.
[18] C. A. Hunter, K. R. Lawson and C. J. Urch, Aromatic interactions.J. Chem. Soc. 2 (2001) 651–669.
[19] DassaultSystemes BIOVIA Discovery Studio Modeling Environment, Release 2017 DassaultSystemes, 2016. http://accelrys.com/products/collaborative-science/biovia-discovery-studio/.
[20] L. El Mchichi, A. Aouidate, F. Z. Chokrafi, A. Ghaleb, T. Lakhlifi and M. Bouachrine, PREDICTION OF BIOLOGICAL ACTIVITY OF PYRAZOLO [3, 4-B] QUINOLINYL ACITAMIDE BY QSAR RESULTS, RHAZES : Grenn and App. Chem. 3 (2018) 79–93.
[21] K.Onodera, K. Satou and H. Hirota, Evaluations of Molecular Docking Programs for Virtual Screening, J. Chem. Inf. Model. 47 (2007) 1609–1618.
[22] L.Gregory, C. Warren, A. Webster, A. Capelli, B. Clarke, J. LaLonde, M. H. Lambert, M. Lindvall, N. Nevins, S. F. Semus, S. Senger, G. Tedesco, I. D. Wall, J. M. Woolven, C. E. Peishoff and M. S. Head, A Critical Assessment of Docking Programs and Scoring Functions,J. Med. Chem. 49 (2006) 5912–5931.
[23] A.Daina, O. Michielin and V. Zoete, SwissADME : a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules, Nat. Publ. Gr. 7 (2016) 1–13.
[24] C. A.Lipinski, F. Lombardo, B. W. Dominy and P. J. Feeney, Experimental and computational approaches to estimate solubility and permeability in drug discovery permeability in drug discovery and development settings, Adv. Drug. Deliv. Rev. 23 (1997) 3_25.
[25] A. K.Ghose, V. N. Viswanadhan and J. J. Wendoloski, A Knowledge-Based Approach in Designing Combinatorial or Medicinal Chemistry Libraries for Drug Discovery. 1. A Qualitative and Quantitative Characterization of Known Drug Databases,J. Comb. Chem. 1 (1999) 55–68.
[26] D. F.Veber, S. R. Johnson, H. Cheng, B. R. Smith, K. W. Ward and K. D. Kopple, Molecular Properties That Influence the Oral Bioavailability of Drug Candidates, J. Med. Chem. 45 (2002) 2615–2623.
[27] W. J.Egan, K. M. Merz and J. J. Baldwin, Prediction of Drug Absorption Using Multivariate Statistics, J. Med. Chem. 43 (2000) 3867–3877.
[28] I.Muegge, S. L. Heald and D. Brittelli, Simple Selection Criteria for Drug-like Chemical Matter, Amer. Chem. soc. 44 (2001)1842_1846.
[29] Y. C.Martin and A. Park, Bioavailability Score, J. Med. Chem. 48 (2005) 3164–3170.
[30] D. E.Pires V, T. L. Blundell and D. B. Ascher, pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures.J Med. Chem. 58 (2015) 4066−4072.
[31] L. Elmchichi, A. Belhassan, T. Lakhlifi, and M. Bouachrine, 3D-QSAR Study of the Chalcone Derivatives as Anticancer Agents, 2020 (2020).